Effects of conversion from sirolimus oral solution to tablets in stable Taiwanese renal transplant recipients

Journal of the Formosan Medical Association

Volumn 104, Issue 1, 2005, Pages 22-28

  Wu, Fe Lin Lin ^a,b   Tsai, Meng Kun ^b   Sun, Shao Wen ^a   Chen, Russel Rhei Long ^c   Huang, Jin Ding ^d   Lee, Po Huang ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAJEN INSTITUTE OF TECHNOLOGY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Dosage forms; Kidney transplantation; Pharmacokinetics; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MALE; TABLET FORMULATION; AREA UNDER THE CURVE; LIVER; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SOLUTION AND SOLUBILITY; TABLET;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; SOLUTIONS; TABLETS;

EID: 14544277202     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sehgal SN: Rapamune, (RAPA, rapamycin, sirolimus): Mechanism of action: immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-40.
2. Vasquez EM: Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000:437-48.
3. Abraham RT: Mammalian target of rapamycin: immunosuppressive drug uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998;10:330-6.
4. Mahalati K, Kahan BD: Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40:573-85.
5. Yatscoff RW: Pharmacokinetics of rapamycin. Transplant Proc 1996;28:970-3.
6. Kumi KA: 21083 Rapamune (sirolimus) oral solution. Clinical pharmacology and biopharmaceutics review (s). [Accessed August 20, 2003]. Available at URL: http://www.fda.gov/eder/ foi/nda/99/21083a_rapamune_clinphrmr.pdf
7. Physicians' Desk Reference. 57th ed. Montvale: Medical Economics Company; 2003:3469-74.
8. Zimmerman JJ, Kahan BD: The pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997;37:405-15.
9. Kahan BD, Napoli KL, Kelly PA, et al: Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000;14:97-109.
10. Kaplan B, Meier-Kriesche HU, Napoli KL, et al: The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53.
11. Anonymous: Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ 1990;24:606-9.
12. Anonymous: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000;284:3043-5.
13. French DC, Saltzgueber M, Hicks DR, et al. HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin Chem 2001;47:1316-9.
14. Kelly PA, Napoli K, Kahan BD: Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. Biopharm Drug Dispos 1999;20:249-53.
15. McAlister VC, Mahalati K, Peltekian KM, et al: A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002;24:346-50.
16. MacDonald A, Scarola J, Burke JT, et al: Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22[Suppl B]:B101-21.
17. McEvoy GK, ed. AHFS drug information. Bethesda: American Society of Health-System Pharmacists, Inc.; 1999:3221-4.
18. Wagayama H, Shiraki K, Sugimoto K, et al: Fatal fulminant hepatic failure associated with benzbromarone [letter]. J Hepatol 2000;32:874.